仁度生物(688193) - 2023 Q4 - 年度业绩预告(更正)

Financial Performance - The company's total operating revenue for the reporting period was adjusted to CNY 16,441.23 million, a decrease of 45.89% compared to the same period last year (CNY 30,384.87 million) [18] - The net profit attributable to the parent company was revised to CNY 318.22 million, reflecting a 64.60% decrease from the previous year's CNY 2,333.14 million [18] - The operating profit was corrected to CNY 544.22 million, down 80.22% from CNY 2,750.71 million in the same period last year [18] - The total profit for the period was adjusted to CNY 476.25 million, a decline of 82.15% compared to CNY 2,668.15 million in the previous year [18] - The company's net profit after deducting non-recurring gains and losses was revised to a range of CNY -1,259.03 million to CNY -1,097.48 million [11] Financial Ratios and Metrics - The weighted average return on equity decreased by 2.11 percentage points to 0.33% from 2.97% in the previous year [11] Assets and Equity - The total assets of the company were reported at CNY 105,627.16 million, a decrease of 3.12% from CNY 108,872.17 million [11] - The equity attributable to the parent company was CNY 95,707.85 million, slightly down from CNY 96,138.47 million [11] Accounting Adjustments - The company has made adjustments to the accounting treatment of government subsidies, impacting the classification of recurring and non-recurring gains [20] - The revised data has been pre-audited by the annual audit firm, with no significant disagreements reported [21]